Results 121 to 130 of about 166,918 (340)
Colorectal Neuroendocrine Tumor pN1 TNM Finding v8 [PDF]
National Cancer Institute
openalex +1 more source
Testicular Neuroendocrine Tumors: A Case Report and Literature Review [PDF]
Abdulaziz A Albalawi +3 more
openalex +1 more source
ABSTRACT Background The annual number of pancreatoduodenectomies (PDs) in the United States has increased over the past decade, but the facility types driving this growth and whether outcomes have improved remain unclear. We aimed to identify characteristics of facilities with increasing PD volumes and assess national trends in centralization ...
Koichi Tomita, Naruhiko Ikoma
wiley +1 more source
Neuroendocrine tumors (NETs) are epithelial neoplasms arising from neuroendocrine cells that are widely distributed throughout the body. The kidney is a rare site for primary NETs and is even rarer as a metastatic site.
Irma Lengu, Santhi Ganesan
doaj +1 more source
Druggable Growth Dependencies and Tumor Evolution Analysis in Patient-Derived Organoids of Neuroendocrine Cancer [PDF]
Talya L. Dayton +34 more
openalex +1 more source
ABSTRACT Background/Objectives Postoperative complications following pancreaticoduodenectomy (PD) remain high, particularly in patients with soft pancreatic texture. Abdominal aortic calcification volume (AACV), a surrogate marker of systemic arteriosclerosis, has been associated with increased surgical risk in lower gastrointestinal procedures ...
Masaki Horiuchi +9 more
wiley +1 more source
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. [PDF]
BackgroundEverolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, is used to treat solid tumors and tuberous sclerosis complex (TSC). Stomatitis, an inflammation of the mucous membranes of the mouth, is a common adverse event associated with ...
Anak, O +10 more
core
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial [PDF]
Matthew H. Kulke +17 more
openalex +1 more source
This study evaluated the impact of distal resection margin (DRM) length on recurrence in 208 patients undergoing surgery for rectal neuroendocrine tumors (NETs). Our findings demonstrate that while oncological safety must unquestionably remain the top priority, a short pathological DRM (< 10 mm) does not increase recurrence risk when R0 resection is ...
Kentaro Sato +8 more
wiley +1 more source
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan [PDF]
Diane Reidy‐Lagunes +11 more
openalex +1 more source

